Read by QxMD icon Read

Recent Patents on Anti-infective Drug Discovery

Manzar Alam, Mohd Imran
BACKGROUND: Hospital wastewater has a high amount of both organic and inorganic matter, as well as high densities of living organisms, including pathogenic, and environmental bacteria. It has been suggested that genes encoding resistance to antibiotic can be located together with heavy metals resistance genes on either the same genetic structure (plasmid), or different genetic structures within the same bacterial strain. Resistance transfer is mainly attributed to conjugation since many antimicrobial resistance genes are situated on mobile elements, such as plasmids and conjugative transposons, whereas renovation and transduction are usually more limited...
July 1, 2018: Recent Patents on Anti-infective Drug Discovery
Komal Sharma, Shams Aaghaz, Kitika Shenmar, Rahul Jain
BACKGROUND: After the era of serendipitous discovery of penicillin and outburst in the discovery and development of highly efficient antibiotics, a surge in resistance against the target specific drugs was observed, primarily due to a combination of selective pressure of antibiotics use and spontaneous mutations. As per the World Health Organization, antibiotic resistance is one of the greatest threats to the mankind. OBJECTIVE: Short antimicrobial peptides (SAMPs) can be considered as a viable therapeutic alternative to conventional antibiotics in tackling resistant microbes...
June 27, 2018: Recent Patents on Anti-infective Drug Discovery
Hossein Kazemian, Hamid Heidari, Jalil Kardan Yamchi, Hengameh Zandi, Asieh Taji, Fateme Yazdani, Roya Ghanavati, Hossein Ali Rahdar, Mohammad Mehdi Feizabadi
BACKGROUND: Mycobacterium tuberculosis as an intracellular pathogen causes tuberculosis (TB). Due to the long time required for treatment, hepatotoxicity of drugs and also emergence of multidrug-resistant (MDR) and extremely drug resistant (XDR) strains, TB is currently a major public health problem. Some medicinal plants possess remarkable activity against Mycobacterium. Among them, Lamiaceae family are of pharmaceutical interest because of their potential antimicrobial properties. The aim of the study was to evaluate the in vitro activities of Satureja rechingeri, Satureja khuzestanica and Zataria multiflora against MDR M...
June 26, 2018: Recent Patents on Anti-infective Drug Discovery
Kanika Thakur, Gajanand Sharma, Bhupinder Singh, Sanjay Chhibber, Om Prakash Katare
BACKGROUND: Topical infections, involving a number of diseases such as impetigo, eczema, pustular acne, psoriasis and infected seborrheic dermatitis are one among the many challenges to health which stand out for their profound impact on human species. The treatment of topical infections has always been a difficult proposition because of the lack of efficacy of existing anti-infectives, longer period of treatment and yet incomplete recovery. The increasing emergence of antibiotic resistant bacterial strains like Staphylococcus aureus, Methicillin-Resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa undermine the need of development of new delivery systems to enhance the therapeutic efficacy of existing topical anti-infectives...
May 28, 2018: Recent Patents on Anti-infective Drug Discovery
Hossein Kazemian
BACKGROUND: Rising rates of antimicrobial resistance among Enterobacteriaceae limit the use of reliably active forms of available drugs. The aim of this study was to investigate the prevalence of fosfomycin (US6794490B2) resistance gene among ESBL producing isolates in Iran. METHOD: We tested 355 isolates of Enterobacteriacea collected from various clinical samples including urine, wounds, blood and other sources during June 2016 to July 2017. Antibiotic sensitivity and extended spectrum beta lactamase (ESBL) production were tested using agar dilution method according to the Clinical and Laboratory Standards Institute (CLSI) guidelines...
May 16, 2018: Recent Patents on Anti-infective Drug Discovery
Fereshteh Satarian, Hamideh Mahmoodzadeh Hosseini, Abdolamir Ghadaksaz, Mohsen Amin, Abbas Ali Imani Fooladi
BACKGROUND: Multi-drug resistance among Pseudomonas aeruginosa (P. aeruginosa) clinical isolates is increasing and becoming a serious problem for public health authorities worldwide. OBJECTIVE: The aim of current study is the introducing a potent antibacterial compound against the resistant P. aeruginosa. The recent patents on antimicrobial properties of extracts drived from Apiaceae family plants (WO2017216602A1, KR20050054247A and KR100285781B1) were used to to assess other member Ferula gummosa (F...
April 26, 2018: Recent Patents on Anti-infective Drug Discovery
Imran Ahmed, Yanyan Fang, Min Lu, Quan Yan, Ahmed Mohamed Kamel El-Hussein, Michael R Hamblin, Tianhong Dai
BACKGROUND: Antibiotic resistance is one of the most serious health threats to modern medicine. The lack of potent antibiotics puts us at a disadvantage in the fight against infectious diseases, especially those caused by antibiotic-resistant microbial strains. To this end, an urgent need to search for alternative antimicrobial approaches has arisen. In the last decade, light-based therapy has made significant strides in this fight to combat antibiotic resistance among various microbial strains...
November 7, 2017: Recent Patents on Anti-infective Drug Discovery
Abul Barkat, Harshita, Sarwar Beg, Javed Naim, Faheem H. Pottoo, Satya P. Singh, Farhan J. Ahmad
Background: Silver nanoparticles (AgNPs), are amongst the utmost striking na-nosized materials that are extensively applied in a variety of biomedical applications which includes diagnostic use, disease management, medical device coating, drug delivery and for personal health care. Discussion: With the growing interest and its application in the health care sector, it is be-coming necessary for a better understanding and exploration of AgNPs mechanism of ac-tion like biological interaction, their possible toxicity, and safety concern to human expo-sure...
October 6, 2017: Recent Patents on Anti-infective Drug Discovery
Hossein Kazemian, Samane Bourbour, Maryam Beheshti, Abbas Bahador
BACKGROUND: Critically ill patients are very susceptible to a variety of disorders and infections during hospitalization in Intensive Care Units [ICU]. Among these problems, nosocomial infections are major causes of morbidity and mortality. METHODS: Nosocomial pneumonias, specifically ventilator associated pneumonias have become a major health care issue. The implication of oral care in hospital presents challenges that can prevent or reduce the risk of nosocomial pneumonias in ICU...
October 2, 2017: Recent Patents on Anti-infective Drug Discovery
Niccolò Riccardi, Filippo Del Puente, Federica Magnè, Lucia Taramasso, Antonio Di Biagio
Background: In 2014, an estimated 1.8 million people died from Mycobacterium tuberculosis (MTB); moreover, 680,000 people developed multidrug-resistant TB (MDR-TB). Methods: Currently available anti-MDR and XDR regimens are long-lasting and expensive, need high adherence and are undermined by a high frequency of adverse drug events, thus leading to a low success rate; moreover, in the last 50 years only two new molecules, bedaquiline (BDQ) and delamanid, have been approved and released for treatment of MDR-TB...
June 19, 2017: Recent Patents on Anti-infective Drug Discovery
(no author information available yet)
No abstract text is available yet for this article.
2017: Recent Patents on Anti-infective Drug Discovery
Abdus Samad, Iram Nazish, Sarwar Beg
No abstract text is available yet for this article.
2017: Recent Patents on Anti-infective Drug Discovery
Jaya Agnihotri, Sobhna Singh, Mohammad Wais, Abhishek Pathak
BACKGROUND: Newly developed vaccine VPM1002 confers paradigm swing in the prophylactic treatment of tuberculosis (TB). Multi-drug resistant and latent TB in adults as well as in underprivileged patients is instigating menace over world population if the host is immune-compromised. METHODS: One third of the world's population is infected with TB. Recently it is estimated around 9.6 million people around the world became sick with TB disease. There were 1.5 million TB-related deaths worldwide...
2017: Recent Patents on Anti-infective Drug Discovery
Praveen K Gaur, Shikha Mishra
BACKGROUND: Tuberculosis (TB) is an infectious disease that resulted in estimated 9.6 million new cases in 2014 and 1.5 million deaths. The available drug regimen for TB is time consuming which more often leads to the patient non compliance which then results in occurrence of drug resistant TB (Multi-drug and extremely drug resistant TB) in several portions of the world. METHODS: The dangerous combinations of TB and HIV is taking its toll on human health. The foremost factor is non- profit associated with the development of anti TB drugs...
2017: Recent Patents on Anti-infective Drug Discovery
Mohammad Taleuzzaman, Vinay Kumar
BACKGROUND: Tuberculosis is one of the major communicable diseases which can be prevented and cured. The prevalence of tuberculosis infection is more despite this disease causes major morbidity and mortality. To establish connection between tuberculosis (TB) related stigma and hindrance in search of a treatment after the inception of symptoms associated with tuberculosis. METHODS: Physicians conducted the interviews using a structured questionnaire. Information from the medical reports available at health care centers (especial results of sputum microscopy, radiological and other investigations) was also distracted...
2017: Recent Patents on Anti-infective Drug Discovery
Zabih Ullah, Mohammad T Athar, Abdus Samad
BACKGROUND: The diseases tuberculosis, triggered by intracellular pathogens, is a major problem for the global medical professionals. Treatments for these diseases through conventional dosage form consist of long-term therapy with multiple drugs, leading to several side effects and contribute to low patient compliance and drug resistance. The pathogens are found to be situated in the intracellular compartments of the cells, which ultimately results in additional blockades to effective treatment...
2017: Recent Patents on Anti-infective Drug Discovery
Srividhya Venkataraman, Tauqeer Ahmad, Mounir A Haidar, Kathleen L Hefferon
BACKGROUND: With an increase in comprehension of the molecular biology of viruses, there has been a recent surge in the application of virus sequences and viral gene expression strategies towards the diagnosis and treatment of diseases. RESULTS: The scope of the patenting landscape has widened as a result and the current review discusses patents pertaining to live / attenuated viral vaccines. The vaccines addressed here have been developed by both conventional means as well as by the state-of-the-art genetic engineering techniques...
2017: Recent Patents on Anti-infective Drug Discovery
Sadaf J Gilani, Ameeduzzafar, Mohammed Jafar, Kashif Shakil, Syed S Imam
BACKGROUND: Nano size based drug delivery systems are an emerging technique with the potential to develop new strategies involving handling of drugs at the nanometer scale. There are many nano-based drug delivery systems that have been extensively reported as drug carriers for the treatment of tuberculosis. METHODS: There are numerous nano sized drug delivery systems like lipid nanoparticles, polymeric micelle, carbon nanotubes and polymeric nanoparticles that have been reported for a long time to treat diseases...
2017: Recent Patents on Anti-infective Drug Discovery
Hayati Demiraslan, Gokcen Dinc, Mehmet Doganay
BACKGROUND: Orf virus is a DNA virus that belongs to the Parapoxvirus genus. The virus is a causative agent of orf in humans or contagious ecthyma in animals which is mostly seen in sheep, goat and cattle. DISCUSSION: Orf is an emerging zoonosis with an increasing number of worldwide outbreaks that have been reported. It is a contagious disease that tends to spread very fast among livestock. The morbidity rate is very high, particularly among young unvaccinated animals...
2017: Recent Patents on Anti-infective Drug Discovery
Mohammad Wais, Mohammad Aqil, Priyanka Goswami, Jaya Agnihotri, Sayyed Nadeem
BACKGROUND: The nanoemulsion based carriers are the most suitable delivery systems for poorly soluble drugs to improve the drugs solubility, permeation of drugs and ultimately increase bioavailability by transdermal therapeutic system. The nanoemulsion for poorly soluble drugs is admirable and offered several advantages over others drug delivery. METHODS: For nanoemulsions formulation, they have to deliver the energetic element at the specific organ with nominal uneasiness...
2017: Recent Patents on Anti-infective Drug Discovery
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"